That and the fact that JF & Co. have had months to counter the AZD0466 demise with either a DEP® Docetaxel or a DEP® Cabazitaxel license deal off the back of the phase 2 top line data and they have failed on both counts over 4 months later ....
...... most other BoD's and CEO's would have put the pedal to the metal after an announcement like this one on AZD0466 in June (below) but not JF & Co. - instead they blow through their own Q3 timelines with nothing announced on the DEP® Docetaxel or a DEP® Cabazitaxel front
.... and of course the Viraleze after market study data could bolster investor confidence if it was as good as we all anticipate and yet they can't even get that out to the market - @joohnno and I agree that this data should take days not weeks or even months ... all this with a while NSW is experiencing a new respiratory virus as well
